However, it was observed that acyclovir did not induce a T-cell response and was therefore determined to not cause ADR events via a binding mechanism with HLA-B*57 01 HLA-B*57 01
But, when acyclovir was subjected to a CD8+ T-cell response assay [36], it was determined that acyclovir did not induce a CD8+ T-cell response [34].
Additionally, the observation that treating HSV-2 infection with acyclovir did not affect the incidence of HIV acquisition [20], suggests that immune damage might already have occurred, and is not reversed by anti-HSV treatment.
If treatment with acyclovir does not significantly alter the complication rate of varicella, then the rate of hospitalisations, and their associated costs, is unlikely to change [ 36].
Reteplase did not influence abciximab binding and did not activate platelets, as measured by P-selectin expression, fibrinogen binding, and platelet aggregation.
Acyclovir encapsulation did not statistically modify AUC or Cmax, but increased t1/2 and MRT 1.3-fold as compared to free acyclovir.
While acyclovir treatment did not affect recognition of LCL by autoantigen and BMRF1-specific T cells, recognition by BNRF1-specific T cells was severely impaired (Fig. 6A).
As reported previously, acyclovir suppression did not reduce HIV-1 transmission to uninfected partners in spite of a 0.25 log10 reduction in plasma HIV-1 levels [ 17], but modestly delayed progression in HIV-1 infected persons [ 18].
However, standard saturation binding experiments with [3H]epibatidine did not reveal biphasic binding under the conditions utilized.
The binding didn't release.
